| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Thoracic/Head and Neck Medical Oncology [D. M. S., W. K. H.], Thoracic Surgery [J. K., J. A. R.], Pathology [J. Y R.], and Clinical Investigation [J. H.,W. N. H.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
2 To whom requests for reprints be addressed, at The University of Texas M. D. Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Box 80, Houston, TX 77030.
With the goal of identifying a potential intermediate biomarker in the multistep process of head and neck cancer development, we conducted immunohistochemical analyses for p53 expression in 33 patients with head and neck squamous cell carcinomas whose tissue sections contained adjacent normal epithelium, hyperplastic, and/or dysplastic lesions. Fifteen of 33 (45%) squamous cell carcinomas of the head and neck expressed p53, but none of four normal control patients (cancer-free nonsmokers) expressed detectable p53 in oral mucosa specimens. To determine when p53 expression is initiated during head and neck tumorigenesis, we examined the normal and premalignant lesions adjacent to the tumors. Five of 24 (21%) samples of normal epithelium adjacent to tumors, 7 of 24 (29%) samples of hyperplasia, and 9 of 20 (45%) samples of dysplasia expressed p53. Quantitative image analysis demonstrated not only a gradual increase in the amount of p53 expression as tissue abnormalities progressed but also a topological change in expression. Whereas p53 expression, when present, was limited to the basal layer in normal epithelium adjacent to tumor, the expression of p53 expanded into the parabasal and superficial layers in hyperplasia and dysplasia. We conclude that p53 expression can be altered in very early phases of head and neck tumorigenesis. Thus, it may be an excellent candidate for risk assessment and may serve as an intermediate biomarker in chemoprevention trials.
1 Supported in part by NIH Grants CA-52501, CA-48364, and CA-45746. D. M. S. is a recipient of the Clinical Oncology Career Development Award (ACS 91-271) from the American Cancer Society.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 9/27/93. Accepted 11/24/93.
This article has been cited by other articles:
|
|
 |
|
  K. Ohuchida, K. Mizumoto, S. Ohhashi, H. Yamaguchi, H. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi, and M. Tanaka S100A11, A Putative Tumor Suppressor Gene, Is Overexpressed in Pancreatic Carcinogenesis. Clin. Cancer Res., September 15, 2006; 12(18): 5417 - 5422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. M. Braakhuis, P. J. F. Snijders, W.-J. H. Keune, C. J. L. M. Meijer, H. J. Ruijter-Schippers, C. R. Leemans, and R. H. Brakenhoff Genetic Patterns in Head and Neck Cancers That Contain or Lack Transcriptionally Active Human Papillomavirus J Natl Cancer Inst, July 7, 2004; 96(13): 998 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Rudin, E. E.W. Cohen, V. A. Papadimitrakopoulou, S. Silverman Jr, W. Recant, A. K. El-Naggar, K. Stenson, S. M. Lippman, W. K. Hong, and E. E. Vokes An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia J. Clin. Oncol., December 15, 2003; 21(24): 4546 - 4552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ganly and B. Singh Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus? J. Clin. Oncol., December 15, 2003; 21(24): 4476 - 4478. [Full Text] [PDF]
|
|
|
|
 |
|
 K Kumpawat and A Chatterjee The usefulness of cytogenetic parameters, level of p53 protein and endogenous glutathione as intermediate end-points in raw betel-nut genotoxicity Human and Experimental Toxicology, July 1, 2003; 22(7): 363 - 371. [Abstract] [PDF]
|
|
|
|
 |
|
 A. G. Banerjee, V. K. Gopalakrishnan, I. Bhattacharya, and J. K. Vishwanatha Deregulated Cyclooxygenase-2 Expression in Oral Premalignant Tissues Mol. Cancer Ther., December 1, 2002; 1(14): 1265 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Cruz, P J F Snijders, V Van Houten, M Vosjan, I Van der Waal, and C J L M Meijer Specific p53 immunostaining patterns are associated with smoking habits in patients with oral squamous cell carcinomas J. Clin. Pathol., November 1, 2002; 55(11): 834 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Calderon-Garciduenas, A. Rodriguez-Alcaraz, G. Valencia-Salazar, A. Mora-Tascareno, R. Garcia, N. Osnaya, A. Villarreal-Calderon, R. B. Devlin, and T. Van Dyke Nasal Biopsies of Children Exposed to Air Pollutants Toxicol Pathol, August 1, 2001; 29(5): 558 - 564. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Shin, N. Charuruks, S. M. Lippman, J. J. Lee, J. Y. Ro, W. K. Hong, and W. N. Hittelman p53 Protein Accumulation and Genomic Instability in Head and Neck Multistep Tumorigenesis Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 603 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Liu, S. Y. Zhang, J. S. Babb, J. A. Ridge, and A. J. P. Klein-Szanto Image Cytometry of Cyclin D1: A Prognostic Marker for Head and Neck Squamous Cell Carcinomas Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 455 - 459. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Roth, N. Hu, M. R. Emmert-Buck, Q.-H. Wang, S. M. Dawsey, G. Li, W.-J. Guo, Y.-Z. Zhang, and P. R. Taylor Genetic Progression and Heterogeneity Associated with the Development of Esophageal Squamous Cell Carcinoma Cancer Res., May 1, 2001; 61(10): 4098 - 4104. [Abstract] [Full Text]
|
|
|
|
|
|
J. Kim, D. M. Shin, A. El-Naggar, J. S. Lee, C. Corrales, S. M. Lippman, W. K. Hong, and W. N. Hittelman Chromosome Polysomy and Histological Characteristics in Oral Premalignant Lesions Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 319 - 325. [Abstract] [Full Text]
|
|
|
|
|
|
C. Heise, M. Lemmon, and D. Kirn Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration Clin. Cancer Res., December 1, 2000; 6(12): 4908 - 4914. [Abstract] [Full Text]
|
|
|
|
|
|
H. J. Roh, D. M. Shin, J. S. Lee, J. Y. Ro, M. A. Tainsky, W. K. Hong, and W. N. Hittelman Visualization of the Timing of Gene Amplification during Multistep Head and Neck Tumorigenesis Cancer Res., November 1, 2000; 60(22): 6496 - 6502. [Abstract] [Full Text]
|
|
|
|
|
|
C.-A. O. Nathan, K. Sanders, F. W. Abreo, R. Nassar, and J. Glass Correlation of p53 and the Proto-Oncogene eIF4E in Larynx Cancers: Prognostic Implications Cancer Res., July 1, 2000; 60(13): 3599 - 3604. [Abstract] [Full Text]
|
|
|
|
|
|
K. Tae, A. K. El-Naggar, E. Yoo, L. Feng, J. J. Lee, W. K. Hong, W. N. Hittelman, and D. M. Shin Expression of Vascular Endothelial Growth Factor and Microvessel Density in Head and Neck Tumorigenesis Clin. Cancer Res., July 1, 2000; 6(7): 2821 - 2828. [Abstract] [Full Text]
|
|
|
|
|
|
M. G. C. T. van Oijen and P. J. Slootweg Oral Field Cancerization: Carcinogen-induced Independent Events or Micrometastatic Deposits? Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 249 - 256. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Shin, L. Mao, V. M. Papadimitrakopoulou, G. Clayman, A. El-Naggar, H. J. C. Shin, J. J. Lee, J. S. Lee, A. Gillenwater, J. Myers, et al. Biochemopreventive Therapy for Patients With Premalignant Lesions of the Head and Neck and p53 Gene Expression J Natl Cancer Inst, January 5, 2000; 92(1): 69 - 73. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Schwartz Biomarkers and Molecular Epidemiology and Chemoprevention of Oral Carcinogenesis Critical Reviews in Oral Biology & Medicine, January 1, 2000; 11(1): 92 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bova, D. I. Quinn, J. S. Nankervis, I. E. Cole, B. F. Sheridan, M. J. Jensen, G. J. Morgan, C. J. Hughes, and R. L. Sutherland Cyclin D1 and p16INK4A Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue Clin. Cancer Res., October 1, 1999; 5(10): 2810 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Saunders, R. MacKenzie, R. Shipman, E. Fransen, R. Gilbert, and R. C. K. Jordan Patterns of p53 Gene Mutations in Head and Neck Cancer: Full-Length Gene Sequencing and Results of Primary Radiotherapy Clin. Cancer Res., September 1, 1999; 5(9): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Posner, P. G. Johnston, R. B. Tishler, J. Andersen, M. Fiorentino, P. M. Busse, L. A. Cavacini, A. D. Colevas, J. Clark, and C. M. Norris The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck Oncologist, December 1, 1998; 3(6): 424 - 431. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Perz and J. G. Kuhn Review : p53 in the pathogenesis, diagnosis, and treatment of cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 75 - 102. [Abstract] [PDF]
|
|
|
|
|
|
U.M. Moll and L.M. Schramm p53--An Acrobat in Tumorigenesis Critical Reviews in Oral Biology & Medicine, January 1, 1998; 9(1): 23 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Spafford, J. Koeppe, Z. Pan, P. G. Archer, A. D. Meyers, and W. A. Franklin Correlation of Tumor Markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 With Survival and Metastasis in Laryngeal Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, June 1, 1996; 122(6): 627 - 632. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
